Maria Joao Diniz, Lisbon, Portugal; Karin Fijnvandraat, Amsterdam

Maria Joao Diniz, Lisbon, Portugal; Karin Fijnvandraat, Amsterdam, Netherlands; Kathelijn Fischer Utrecht, Netherlands; Pal Andre Holme, Oslo, Norway; Katahrina Holstein, Hamburg, Germany; Fernanda Lopez, La Coruna, Spain. The authors stated that they had no interests BAY 80-6946 mouse which might be perceived as posing a conflict or bias. The European Haemophilia Therapy Standardisation Board is an independent group of clinicians supported and facilitated by an unrestricted grant from Baxter Bioscience Europe. “
“A 56-year-old African American male with

severe haemophilia A [baseline factor VIII (FVIII) activity <1%] and chronic hepatitis C virus infection started annual serial monitoring of prostate-specific check details antigen (PSA) at age 40 because of a family history of prostate cancer (his father died from the disease at

age 63). His most recent PSA level was 4.4 ng L−1; previous values were <3 ng L−1. Digital rectal examination was unrevealing. "
“Factor replacement therapy for the treatment of moderate to severe haemophilia A and B can be complicated by the production of inhibitory alloantibodies to factor VIII (FVIII) or factor IX. Treatment with the nanofiltered anti-inhibitor coagulant complex, Factor Eight Inhibitor Bypassing Activity (FEIBA NF), is a key therapeutic option for controlling acute haemorrhages in patients with high-titre click here inhibitors or low-titre inhibitors refractory to replacement therapy. Given the high risk

for morbidity and mortality in haemophilia patients with inhibitors to FVIII or FIX, we conducted this Phase 3 prospective study to evaluate whether prophylaxis with FEIBA NF is a safe and effective treatment option. Over a 1-year period, 17 subjects were treated prophylactically (85 ± 15 U kg−1 every other day) while 19 subjects were treated on demand. The median (IQR) annualized bleeding rate (ABR) during prophylaxis was 7.9 (8.1), compared to 28.7 (32.3) during on-demand treatment, which amounts to a 72.5% reduction and a statistically significant difference in ABRs between arms (P = 0.0003). Three (17.6%) subjects (ITT) on prophylaxis experienced no bleeding episodes, whereas none treated on demand were bleeding episode-free. Total utilization of FEIBA NF for the treatment of bleeding episodes was significantly higher during on-demand therapy than prophylaxis (P = 0.0067). There were no differences in the rates of related adverse events between arms.

Comments are closed.